 |
Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic® for Beta-thalassemia
May 24, 2013
|
11.5 KB |
|
| |
RICHMOND, Calif., May 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted the Company a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nucleas...
|
|
Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases
May 20, 2013
|
14.6 KB |
|
| |
RICHMOND, Calif., May 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire AG...
|
|
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
May 15, 2013
|
62.8 KB |
|
| |
RICHMOND, Calif., May 15, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented...
|
|
Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
May 9, 2013
|
8.1 KB |
|
| |
RICHMOND, Calif., May 9, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:00 am PT on Thursday, May 16, 2013, at the B...
|
|
Sangamo BioSciences Reports First Quarter 2013 Financial Results
May 8, 2013
|
16.3 KB |
|
| |
RICHMOND, Calif., May 8, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2013 financial results and accomplishments.
(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)
For the first quarter ended March 31, 2013, Sangamo reported a consolidated net loss of $6.9 million, or $0.13 ...
|
|
Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
May 1, 2013
|
8.4 KB |
|
| |
RICHMOND, Calif., May 1, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2013 financial results on Wednesday, May 8, 2013, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and ...
|
|
Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
Apr 24, 2013
|
8.0 KB |
|
| |
RICHMOND, Calif., April 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:50 pm ET on Wednesday, May 1, 2013, at th...
|
|
Sangamo BioSciences Announces Presentation At Regen Med Investor Day
Apr 10, 2013
|
9.7 KB |
|
| |
RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.
(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)
Organized...
|
|
Sangamo Presents New Clinical Data at CROI 2013 Demonstrating Persistent Immune System Improvements After Treatment With ZFN Therapeutic® SB-728-T
Mar 6, 2013
|
17.4 KB |
|
| |
RICHMOND, Calif., March 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced new data from its program to develop a 'functional cure' for HIV/AIDS in two presentations at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), held in Atlanta from March 3 to 6, 2013.
(Logo: http://photos.prnewswire....
|
|
Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Mar 5, 2013
|
8.0 KB |
|
| |
RICHMOND, Calif., March 5, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 4:45 pm ET on Wednesday, March 13, 2013, at t...
|
|
Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Feb 27, 2013
|
8.1 KB |
|
| |
RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10...
|
|
Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
Feb 7, 2013
|
8.3 KB |
|
| |
RICHMOND, Calif., Feb. 7, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at the following conferences:
The Leer...
|
|
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Feb 6, 2013
|
17.9 KB |
|
| |
RICHMOND, Calif., Feb. 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2012 financial results and accomplishments.
(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)
For the fourth quarter ended December 31, 2012, Sangamo reported a consolidated net loss of $3.5...
|
|
Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Jan 30, 2013
|
8.4 KB |
|
| |
RICHMOND, Calif., Jan. 30, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2012 financial results on Wednesday, February 6, 2013, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the pub...
|
|
Sangamo BioSciences Announces Presentation At 31st Annual J.P. Morgan Healthcare Conference
Jan 2, 2013
|
8.1 KB |
|
| |
RICHMOND, Calif., Jan. 2, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:30 am PT (1:30 pm ET) on Wednesday, January...
|
|
Sangamo Biosciences Announces Presentation Of Data Demonstrating A Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies At American Society Of Hematology Meeting
Dec 10, 2012
|
12.1 KB |
|
| |
RICHMOND, Calif., Dec. 10, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating the successful application of its In Vivo Protein Replacement Platform. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the platform enables the permanent prod...
|
|
Sangamo BioSciences Provides Comprehensive Overview Of Company's ZFP Therapeutic® Development Programs At Its 2012 Analyst Briefing
Dec 6, 2012
|
12.7 KB |
|
| |
NEW YORK, Dec. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics® as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. The presentation, ...
|
|
Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Nov 27, 2012
|
7.7 KB |
|
| |
RICHMOND, Calif., Nov. 27, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced today that it will host a live webcast of its upcoming Analyst and Investor Briefing which will be held in New York City at 5:00 pm ET on Thursday, December 6, 2012. During the briefing, members of Sangamo's management team will provide an update on...
|
|
Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
Nov 6, 2012
|
7.7 KB |
|
| |
RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:30 pm ET on Tuesday, November 13, 2012, at t...
|
|
Sangamo BioSciences Reports Third Quarter 2012 Financial Results
Oct 24, 2012
|
16.3 KB |
|
| |
RICHMOND, Calif., Oct. 24, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2012 financial results and accomplishments.
For the third quarter ended September 30, 2012, Sangamo reported a consolidated net loss of $5.8 million, or $0.11 per share, compared to a net loss of $9.6 million, or $0.18 per sh...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
